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ABSTRACT
Tylophorine compounds have been the focus of drug development for decades. 
Tylophorine derivatives exhibit anti-cancer activities but their cellular targets 
remain unknown. We used a biotinylated tylophorine derivative to probe for the 
interacting cellular target(s) of tylophorine. Tylophorine directly binds to caprin-1 
and consequently enhances the recruitment of G3BP1, c-Myc mRNA, and cyclin D2 
mRNA to form a ribonucleoprotein complex. Subsequently, this tylophorine targeted 
ribonucleoprotein complex is sequestered to the polysomal fractions and the protein 
expressions of the associated mRNA-transcripts are repressed. Caprin-1 depleted 
carcinoma cells become more resistant to tylophorine, associated with decreased 
formation of the ribonucleoprotein complex targeted by tylophorine. Consequently, 
tylophorine downregulates c-Myc and cyclins D1/D2, causing hypophosphorylation 
of Rb and suppression of both processing-body formation and the Warburg effect. 
Gene expression profiling and gain-of-c-Myc-function experiments also revealed that 
the downregulated c-Myc contributes to the anti-oncogenic effects of tylophorine 
compounds. Furthermore, the potent tylophorine derivative dibenzoquinoline-33b 
elicited a similar effect, as c-Myc protein levels were also decreased in xenograft 
tumors treated with dibenzoquinoline-33b. Thus, tylophorine compounds exert anti-
cancer activity predominantly by targeting and sequestering the caprin-1 protein and 
c-Myc mRNA associated ribonucleoprotein complex. 
INTRODUCTION
c-Myc is a transcriptional factor that regulates a 
variety of cellular processes including the activity of 
cyclin D-Cdk (cyclin-dependent kinase) [1], the Warburg 
effect in cancer cell metabolism[2, 3], and cellular mRNP 
processing[4, 5]. Myc expression is deregulated in a wide 
range of human cancers and is therefore a therapeutic 
target. Recently, it was found that the RNA-binding 
protein human antigen R inhibits c-Myc expression by 
recruiting miRNA let-7-loaded RISC (RNA miRNA-
induced silencing complex) to the c-Myc 3’UTR [6]. This 
raises the possibility of developing c-Myc inhibitors by 
targeting its associated RNP.
Cyclin D (cyclin D1, cyclin D2, and cyclin D3 
encoded in human cells) is a member of the cyclin protein 
family. These proteins are involved in the regulation of 
cell cycle progression for the transition of G1 to S phase 
[7]. c-Myc has been shown to regulate transcription of 
genes involved in cell cycle including cyclin D[1]. The 
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retinoblastoma tumor suppressor protein (pRb) is one 
of the best known substrates of active cyclin D-Cdk4/6 
complexes. Thus, the phosphorylated pRb is a common 
downstream effector of cyclins D1[8, 9], D2[10, 11], and 
c-Myc[1, 7]. 
The tumor suppressor protein pRb is dysregulated 
in several major cancers. pRb is a stable protein and 
is phosphorylated by several Cdks, which down-
regulates its activity. Active pRb acts as a tumor 
suppressor by inhibiting cell cycle progression[7]. In 
the hypophosphorylated active form, pRb sequesters the 
transcriptional factor E2F. When pRb is inactivated by 
hyperphosphorylation, it releases E2F, permitting E2F to 
execute its cell cycle regulatory functions. Therefore, the 
hyperphosphorylation of pRb during late G1 phase enables 
the activation of E2F-dependent transcription, e.g cyclin 
A2[12].
Caprin-1(Cytoplasmic activation- and proliferation-
associated protein 1) is ubiquitously expressed, and 
its phosphorylation is required for normal cell cycle 
progression from the G1 to S phase. Caprin-1 co-localizes 
with G3BP1 (Ras GTPase-activating protein-binding 
protein 1) within the cytoplasmic RNA granules that 
are associated with microtubules. This caprin-1/G3BP1 
complex is thought to regulate the transport and translation 
of mRNAs whose protein products are involved in 
proliferation and migration in multiple cell types because 
the carboxyl-terminal region of caprin-1 selectively binds 
to c-Myc or cyclin D2 mRNAs[13]. Collectively, the 
caprin-1, G3BP1, c-Myc mRNA, and Cyclin D2 mRNA 
complex represents a function-specific RNP complex and 
is required for important cellular events.
Natural products constitute a successful and 
promising resource for drug discovery. The elucidation 
of the cellular targets of therapeutic natural products not 
only contributes to the identification of valuable novel 
drug targets for future development, but also guides 
subsequent molecular pharmacology and mode-of-action 
studies[14, 16]. Tylophorine-related natural compounds, 
which are found in the Asclepiadaceae and Moraceae plant 
families, exhibit multiple biological activities (e.g., anti-
cancer, anti-coronavirus, and anti-inflammatory activities)
[17-24]. Tylophorine compounds have been the focus of 
drug development as therapeutic agents since the 1960s, 
whereas tylocrebrine failed phase I clinical trials due to 
neurotoxicity [17]. Although several modes of action for 
anti-cancer tylophorine compounds have been reported[20, 
25-28], their direct cellular target(s) and related pathways 
remain to be elucidated[24]. In particular, the fundamental 
mechanisms underlying the broad spectrum, drug-resistant 
cancer cell inhibitory activities of tylophorine compounds 
remain to be investigated. 
We designed and synthesized a biotinylated 
tylophorine compound which retained the molecular 
targeting moiety, enabling the probing of direct cellular 
target(s). In combination with proteomic approaches and 
further molecular mechanism studies, the anti-cancer 
activities of the tylophorine compounds were elucidated. 
Our results provide a mechanistic basis for developing the 
tylophorine derived compounds into anti-cancer drugs. 
The identified cellular target(s) of tylophorine represent 
novel drug targets for anti-cancer therapeutic applications. 
RESULTS
Synthesis of a biotinylated tylophorine analogue
Previously, we reported that the non-planar structure 
between the two major phenanthrene and indolizidine/
quinolizidine moieties, as well as the planarity and 
rigidity of the indolizidine/quinolizidine moiety of 
tylophorine compounds, significantly affect the activities 
of tylophorine analogues[19]. Recently, we successfully 
synthesized potent tylophorine-derived dibenzoquinolines 
that elicit the same biological functions as traditional 
pentacyclic tylophorine compounds[23]. Therefore, we 
concluded that the angular dibenzoquinoline moiety in 
tylophorine compounds is responsible for the interactions 
with their direct target molecule(s). Thus, we sought to 
design and synthesize a biotinylated tylophorine-derived 
dibenzoquinoline (Fig. 1A), referred to herein as the 
“biotinylated tylophorine”, to probe direct interacting 
molecules in cells. The biotinylated tylophorine retained 
anti-cancer cell activity with IC50 values of ~13-30 µM 
against HONE-1, MCF7, or NUGC-3 carcinoma cells (see 
Supplemental Table 1).
Identification of direct targets of tylophorine 
via pull-down experiments with biotinylated 
tylophorine
HONE-1 cell lysates were incubated with the 
vehicle control (dimethyl sulfoxide, DMSO), biotin-X-
SSE, or biotinylated tylophorine prior to the addition 
of streptavidin in a pull-down experiment. The pulled-
down complex was subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and 
silver staining to analyze the proteins that specifically 
interacted with the biotinylated tylophorine. A total 
of 6 protein bands were specifically associated with 
biotinylated tylophorine compared to biotin-X-SSE (Fig. 
1B); these bands were excised for further matrix-assisted 
laser desorption ionization-time of flight (MALDI-TOF) 
mass spectrometry (MS) proteomics analyses. The 
potential tylophorine-interacting proteins were identified 
by Mascot data analysis (Fig. 1C and Supplemental Table 
2), and the specific interaction of these proteins with 
biotinylated tylophorine was validated by western blot 
analysis (Fig. 1D). Caprin-1, α-actinin-4, nucleolin, the 
splicing factor (PSF), polyadenylate-binding protein-1 
Oncotarget2150www.impactjournals.com/oncotarget
(PABP-1), heterogeneous nuclear ribonucleoprotein M3-
M4 (hnRNPM3-M4), hnRNPQ, TATA-binding protein-
associated factor 2N isoform 1 (TAF-15), G3BP1, 40S 
ribosomal protein S6 (S6), phosphorylated S6 (p-S6), 
and ribosomal protein S3 were specifically pulled down 
by biotinylated tylophorine compared to biotin-X-SSE 
or DMSO, but the expression levels of these proteins in 
tylophorine-treated HONE-1 or MCF7 carcinoma cells 
were not significantly altered compared with DMSO-
treated cells, with the exception of p-S6, which was 
significantly increased (Fig. 1E). 
The pull-down of ribosome proteins by biotinylated 
tylophorine was not unexpected because tylocrebrine was 
previously reported to inhibit the translocation of peptidyl-
tRNA in ribosomes by 54%, although a tylocrebrine 
concentration as high as 100 µM was used[29]. Because 
tylophorine compounds exert significant anti-cancer 
activities, generally with IC50 values ranging from 
hundreds to a few nM[22-24], we further examined other 
proteins identified to seek specific targets for anti-cancer.
Tylophorine associates with an RNP complex 
containing caprin-1, G3BP-1, c-Myc mRNA, and 
Cyclin D2 mRNA
Caprin-1 was identified among the molecules 
that were pulled down by biotinylated tylophorine, and 
we focused on this protein because it is ubiquitously 
expressed and required for normal progression through the 
G1-S phase[13]. We performed co-immunoprecipitation 
using a caprin-1 antibody to assess the associated complex 
members. We identified α-actinin-4, G3BP1, and p-S6 
within the caprin-1 complex in the presence of biotinylated 
tylophorine (Fig. 2A). Because caprin-1 and G3BP1 were 
previously reported to associate and co-localize within 
RNA-rich cytoplasmic granules[13], we further dissected 
the association of c-Myc mRNA and cyclin D2 mRNA in 
HONE-1 cells by RT-PCR analysis of the products from 
the pull-down experiment with biotinylated tylophorine 
(Fig. 2B). We also demonstrated the direct, but weak, 
interaction of biotinylated tylophorine with caprin-1 in 
Figure 1: The application of biotinylated tylophorine to probe its direct interacting cellular targets in carcinoma cells. 
A. Scheme for the synthesis of biotinylated tylophorine (BT), a dibenzoquinoline derivative. B & C. Pull-down experiment in HONE-1 
cell lysates to identify potential molecular targets of tylophorine. BT and biotin-X-SSE were used to pull down the interacting molecules 
by using streptavidin beads. The lane labelled “3x sample” was loaded with 3-fold-amount of the BT pull-down and the lane labelled 
“3x lysate” was loaded with the BT pull-down from a 3-fold-amount of the lysate. The indicated bands in the silver-stained SDS-PAGE 
gel (B) were subjected to proteomic studies for Mascot analysis as potential targets (C). D. Immunoblot analyses with the indicated 
antibodies to confirm the molecules identified by Mascot analysis as potential tylophorine-interacting targets in the pulled-down complexes. 
E. Immunoblot analysis of the identified intracellular targets of biotinylated tylophorine in the total carcinoma cell lysates of HONE-1 
or MCF7 cells treated with tylophorine for 24 h. The downregulation of cyclin A2[20] and upregulation of c-Jun[25] protein expression 
induced by tylophorine treatment were considered as internal controls in addition to the loading control GAPDH. The results shown are 
representative of 3 independent experiments. 
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another pull-down experiment using purified recombinant 
caprin-1 protein (Fig. 2C). 
Furthermore, sedimentation fractionation revealed 
that caprin-1, G3BP1, p-S6, c-Myc mRNA, and cyclin 
D2 mRNA co-localized within polysomal fractions upon 
tylophorine treatment (Fig. 2D-a); this colocalization 
did not occur in vehicle-treated HONE-1 cells (Fig. 2D-
b). Moreover, a low abundance of cyclin D2 has been 
observed in certain carcinoma cell lines[30-32], such as 
MCF7 (Fig. 3A); under certain conditions, the loss of a 
specific cyclin can be compensated by the presence of 
others [33, 34]. Further investigation revealed that cyclin 
D1 mRNA co-localizes with the caprin-1, G3BP1, and 
c-Myc mRNA-associated RNP complex (Fig. 2B), as well 
as within polysomal fractions (Fig. 2D). These results 
indicate that either cyclin D1 or D2 mRNAs might be 
sequestered by biotinylated tylophorine (Fig. 2B & 2D) 
or associated with a tylophorine-targeted RNP complex in 
tylophorine-treated HONE-1 cells (Fig. 2D). 
Figure 2: The association of caprin-1 and G3BP1 with c-Myc and cyclins D1/D2 mRNAs through tylophorine. A. 
The co-immunoprecipitation of caprin-1 with α-actinin-4, G3BP1, and p-S6 from the HONE-1 cell lysate in the presence of biotinylated 
tylophorine was detected by immunoblot analyses with the indicated antibodies. B. Biotinylated tylophorine pulled down the mRNAs 
for c-Myc and cyclins D1 and D2 from the HONE-1 cell lysate as detected by RT-PCR with the indicated primer pairs. C. Purified 
recombinant caprin-1 protein physically associates with biotinylated tylophorine. Human caprin-1 was transiently expressed in HEK-293 
cells, affinity-purified as described in the Methods section, and applied to a pull-down experiment with biotinylated tylophorine. The 
protein was subsequently detected by immunoblot analysis using an antibody against human caprin-1. D. Polysome profile analysis (by 
sucrose gradient sedimentation) and protein (by western, upper panel) and RNA (by qRT-PCR, lower panel) analyses of sucrose gradient 
fractions for the co-localization of caprin-1, G3BP1, c-Myc mRNA, cyclin D1 mRNA, and cyclin D2 mRNA in the tylophorine-induced 
RNP complex from the lysates of HONE-1 cells treated with either with tylophorine (2 µM) (Fig. 2D-a) or vehicle (0.1% DMSO) (Fig. 
2D-b) for 24 h. BT, biotinylated tylophorine. The results shown are representative of 3 independent experiments. 
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Tylophorine represses the protein expression of 
c-Myc and cyclins D1/D2 but does not decrease 
their mRNA levels through association with 
caprin-1
We examined the effect of tylophorine on the 
expression of c-Myc and cyclins D1/D2 based on the 
above pull-down results. Tylophorine treatment increased 
the mRNA levels of c-Myc and cyclin D1 in both HONE-1 
and MCF7 cells. Cyclin D2 mRNA levels were increased 
only in HONE-1 cells upon tylophorine treatment since 
cyclin D2 mRNA level was undetectable in MCF7 cells 
as reported [30-32], regardless of tylophorine treatment 
(Fig. 3A). However, c-Myc and cyclin D1 protein levels 
were diminished in HONE-1, MCF7, or NUGC-3 cells 
upon tylophorine treatment (Fig. 3B). In addition, and 
as expected, cyclin D2 protein levels were decreased in 
tylophorine treated HONE-1 and NUGC-3 but no cyclin 
D2 were detectable in MCF7 cells (Fig. 3B). Furthermore, 
we used TAMRA to label the newly synthesized 
protein after tylophorine treatment and followed by 
immunoprecipitation and western blot to detect the 
proteins of interest. We found that the de novo protein 
syntheses of c-Myc and cyclinD1/D2 were diminished 
upon tylophorine treatment but not that of G3BP1 
protein (Fig. 3C). When HONE-1 cells were depleted 
with caprin-1 by siRNA, the resultant cells became more 
Figure 3: The effect of tylophorine through caprin-1 on c-Myc, cyclin D1, and cyclin D2 expression in carcinoma cells. 
A. Semi-quantitative RT-PCR analyses of the effect of tylophorine on the mRNA levels of c-Myc, cyclin D1, and cyclin D2. The relative 
expression levels of each mRNA were normalized with their respective internal loading control GAPDH. B. Immunoblot analyses of the 
effects of tylophorine on protein expressions related to the caprin-1-associated RNP complex and their common downstream target pRb. 
The carcinoma cells were treated with tylophorine (2 µM) for 24 h prior to semi-quantitative RT-PCR or western blotting analyses with the 
indicated gene primer pairs or antibodies. C. Tylophorine repressed the de novo protein syntheses of c-Myc and cyclins D1/D2. TAMRA-
labeled newly synthesized proteins from tylophorine treated HONE-1 cells were immunoprecipitated with specific antibody as indicated 
and then detected by western blotting with indicated antibody. D. Depletion of caprin-1 increased carcinoma cells’ resistance to tylophorine 
or DBQ 33b treatments. HONE-1 cells were transfected with control shRNA or CAPRIN1 shRNA plasmids respectively, and then selected 
with puromycin. The resultant cells were analyzed by western blotting for validation of caprin-1 depletion before subjected to measurement 
of cell growth IC50 values by tylophorine or DBQ 33b. A 2-tailed unpaired Student’s t test was used to evaluate the p-value between two 
groups. E & F. The effect of caprin-1 depletion on the association of tylophorine targeted RNP complex. Caprin-1 depleted HONE-1 lysates 
described in D were subjected to pull-down assays with biotinylated tylophorine or biotin-X-SSE. Immunoblot (E) and Semi-RT-qPCR 
analyses (F) were used to detect the protein and mRNA components in the tylophorine-associated RNP complex. The sequences of the gene 
primer pairs used are listed in Supplemental Table 3. BT, biotinylated tylophorine. The results shown are representative of 3 independent 
experiments. *, p<0.05.
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resistant to tylophorine compounds with an ~2 fold higher 
IC50 value for tylophorine and its potent derivative DBQ 
33b (dibenzoquinoline-33b) (Fig. 3D). Accordingly, the 
amounts of G3BP1 protein (Fig. 3E) and mRNAs of 
c-Myc and cyclins D1/D2 pulled down by biotinylated 
tylophorine were decreased (Fig. 3F).
These results suggest that tylophorine blocked the 
protein expressions of c-Myc and cyclins D1/D2 through 
association with caprin-1 thereby downregulating their 
downstream signaling pathways to exert the anti-cancer 
activity. The roles of tylophorine-downregulated signaling 
pathways of c-Myc and cyclins D1/D2 in anti-cancerous 
tylophorine were investigated as followed. 
Tylophorine hypophosphorylates and activates 
pRb through repressing protein expression of 
cyclins D1/D2 and c-Myc
pRb protein, a common downstream effector of 
cyclins D1[8, 9] and D2[10, 11] and c-Myc[1, 7], was 
further examined for tylophorine effects on the anticancer 
activity. pRb was hypophosphorylated to the active form 
in tylophorine-treated carcinoma cells, whereas its protein 
expression levels remained unchanged (Fig. 3B); this 
result was expected because the protein expressions of 
the pRb’s upstream regulators, cyclins D1[8, 9]/ D2[10, 
11] and c-Myc[1, 7], were reduced by tylophorine 
treatment thereby decreasing the phosphorylation of pRb 
(Fig. 3B). Cyclin A2 was downregulated by tylophorine, 
which partially accounts for the G1 arrest induced by 
tylophorine[20, 25]. The cyclin A2 promoter region 
contains two E2F regulatory sites. When either cyclin D2 
(Fig. 4A-upper panel) or cyclin D1 (Fig. 4A-lower panel) 
was overexpressed, the downstream hyperphosphorylation 
of pRb resumed, thereby upregulating E2F-mediated 
cyclin A2 expression[35] in tylophorine-treated cells (Fig. 
4A). 
Moreover, ectopic overexpression of c-Myc also 
restored the hyperphosphorylation of the downstream 
effector pRb as well as cyclin A2 expression. Strikingly, 
the expression of cyclins D1/D2 was not restored by 
ectopic overexpression of c-Myc (Fig. 4B), even though 
cyclins D1/D2 are downstream target genes of c-Myc 
signaling [36, 37]. The resulting hyperphosphorylation of 
pRb can be, at least in part, attributed to increased levels 
of cyclin B1[38] (Fig. 4B), a c-Myc target and another 
upstream effector of pRb, or feedback from upregulated 
cyclin A2, as ectopic overexpression of cyclin A2 was 
also able to partially resume the hyperphosphorylation of 
pRb (Fig. 4C). These results further emphasize that even 
ectopically expressed c-Myc can upregulate or stabilize 
the transcription of cyclins D1 and D2, but their mRNA is 
subject to sequestration by tylophorine in the caprin-1 and 
c-Myc mRNA-associated RNP complex, thereby blocking 
their translation. Therefore, ectopically expressed c-Myc 
resumed the hyperphosphorylation of pRb through a 
pathway independent of cyclins D1/D2.
In summary, active hypophosphorylated pRb can 
be inactivated to hyperphosphorylated form upon the 
overexpression of cyclins D1/D2 or c-Myc in tylophorine-
treated carcinoma cells. The hypophosphorylation of pRb 
plays an important role in facilitating the anti-cancer 
activity of tylophorine. Accordingly, the downstream 
pathway targets of c-Myc as well as those of cyclins D1 
and D2 (e.g. pRb, cyclin A2 and cyclin B1) were also 
downregulated and contributed to the anti-cancer activity 
of tylophorine.
The effects of tylophorine treatment on cellular 
events specifically regulated by c-Myc such as 
the Warburg effect in cancer metabolism and 
formation of processing bodies
To demonstrate the functional consequences of 
c-Myc signaling inhibition by tylophorine, cellular events 
specifically regulated by c-Myc such as the Warburg effect 
in cancer metabolism, and formation of processing bodies 
(P-bodies), were examined. 
Although most tylophorine-treated cells were 
viable, their proliferation was completely suppressed[20], 
and no significant apoptosis occurred[25]. Therefore, 
we examined the effect of tylophorine treatment on 
GLS1 (Glutaminase type 1)[3] and LDHA (Lactate 
dehydrogenase)[2], c-Myc-targeted genes that mediate 
the cancer cell nutrient supply via the Warburg effect, and 
observed that the protein expression levels of these genes 
were downregulated in tylophorine-treated carcinoma 
cells (Fig. 5A and 5B). When c-Myc was overexpressed in 
tylophorine-treated HONE-1 cells, the protein expression 
levels of GLS1 and LDHA were restored (Fig. 5B). 
Thus, tylophorine downregulated the Warburg effect by 
suppressing c-Myc protein expression levels. 
The levels of eIF4E [4, 5] (a c-Myc target gene) 
which is involved in cytoplasmic mRNP processing, 
were significantly reduced in carcinoma cells, as were 
the levels of Dcp1a, another constituent of P-bodies 
[39-41] (Fig. 5A). We next examined the effects of 
tylophorine treatment on P-body formation using confocal 
immunofluorescent microscopy, which indicated that both 
the numbers of P-bodies and the populations of cells that 
exhibited P-bodies were dramatically decreased to 0~5% 
upon tylophorine treatment in HONE-1, NUGC-3, or 
HeLa cells (Fig. 5C).
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Figure 4: Gain-of-function experiments for tylophorine-induced decreased protein expression of cyclin D1, cyclin D2, 
and c-Myc. A. Ectopically overexpressed cyclin D1 or D2 restored the hyperphosphorylation of pRb and the expression of cyclin A2. B. 
Ectopically overexpressed c-Myc rescued the biological function of its downstream effectors (e.g., cyclin B1 and p-pRb) but not the protein 
expression of cyclin D1 and D2. C. Ectopically overexpressed cyclin A2 moderately restored the hyperphosphorylation of pRb. HONE-1 
cells were transfected with the indicated expression vectors for 24 h prior to treatment with either vehicle (DMSO) or tylophorine at the 
indicated concentrations for an additional 24 h. The resulting cell lysates were analyzed by western blotting with the indicated antibodies. 
The relative expression or phosphorylation levels of each protein were normalized with their respective internal loading control α-tubulin 
or GAPDH. The results shown are representative of 3 independent experiments. 
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Figure 5: The effects of tylophorine compounds in c-Myc regulated Warburg effect and P-body (processing body) 
formation. A. Tylophorine treatment decreased the protein expressions of GLS1 and LDHA involved in Warburg effect as well as eIF4E 
and DCP1a in P-body formation. B Ectopically Overexpressed c-Myc restored the protein expressions of GLS1 and LDHA. The relative 
expression levels of each protein were normalized with their respective internal control GAPDH. C. Tylophorine treatment decreased the 
formation of P-bodies. The P-bodies were visualized by immunofluorescent staining using anti-Dcp1a-TRITC (in red) and eIF4E-FITC 
(in green). DAPI (in blue) was used for nuclear counterstaining. The carcinoma cells were treated with DMSO, tylophorine (2 µM), or 
nocodazole (30 ng/mL) for 24 h prior to western blotting or immunofluorescent staining analyses with the indicated antibodies. The 
percentage of the cell population exhibiting P-bodies and the relative percentages of the total number of P-bodies in each treatment were 
counted with Image-J software (National Institutes of Health) and listed. Nocodazole was used an additional compound control that induces 
formation of P-bodies. The results shown are representative of 3 independent experiments.
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Tylophorine downregulates c-Myc protein 
expression levels in carcinoma cells in vitro and 
in vivo
Because tylophorine-related alkaloids potently 
inhibit the growth of a wide variety of drug-sensitive 
and drug-resistant cancer cell lines, we evaluated c-Myc 
protein expression levels in a panel of carcinoma cell 
lines (13 carcinoma cell lines from 9 types of tumors 
and 2 fibroblast cell lines) with tylophorine treatment. 
We observed the sustained blockade of c-Myc protein 
expression in each of the individual carcinoma cell lines 
upon treatment with tylophorine or its potent derivative 
DBQ 33b[23] but not in the fibroblast cell lines. c-Myc 
protein expression levels were reduced to 1-33% (Fig. 
6A), whereas c-Myc mRNA levels were increased by 
1.5-4.5-fold (Figs. 3A, 6B, & 6C). We also performed 
gene expression profiling and analysis of the c-Myc 
downstream pathways that were affected by tylophorine 
or DBQ 33b (Fig. 6B), as well as validation by RT-qPCR 
(Fig. 6C). Both compounds increased the expression of 
c-Myc mRNA by ~2-4-fold; the mRNA levels of genes 
that were upregulated by c-Myc were decreased (e.g., 
cyclin A2, cyclin B1, SERBP1, PRDX3, and POLR3G), 
and the mRNA levels of genes that were downregulated 
by c-Myc increased (e.g., GADD45A, and THBS1) (Fig. 
6B and 6C). These results are consistent with the above 
observation that increased c-Myc mRNA levels and 
decreased c-Myc protein levels occurred in tylophorine-
treated cells, which led to negative regulation of c-Myc 
effector pathways. The genes, whose expression was 
upregulated or downregulated by tylophorine and 
DBQ 33b, associated with the function of c-Myc in 
carcinogenesis are shown in Figure 6D. 
In a mouse tumor model using human lung A549 
carcinoma xenografts, DBQ 33b significantly reduced the 
tumor volume in a dose-dependent manner[23]. Finally, we 
examined the c-Myc protein and its mRNA expression in 
these xenograft tumors[23]. Our results further confirmed 
reductions in c-Myc protein levels with concomitant 
increases in its mRNA levels in a dose-dependent manner 
in the DBQ 33b-treated tumors compared to the vehicle-
treated tumors (Fig. 6E and 6F). These results correlated 
with the in vivo anti-tumor activity[23] and in vitro anti-
cancer results for DBQ 33b (Fig. 6A, 6B, & 6C).
DISCUSSION
In this study, it was found that tylophorine 
compounds exert their anti-cancer activities via targeting 
the caprin-1, G3BP1, c-Myc mRNA, and cyclin D2 
or D1 mRNAs containing RNP complex, inhibiting 
the functions of the RNP components and blocking the 
protein translation of the corresponding mRNA transcripts 
(e.g., c-Myc, cyclin D2, and cyclin D1, as well as their 
downstream pathway components such as pRb) (Fig. 7). 
Because abnormal c-Myc signaling in cancer cells has 
been associated with oncogenicity, the downregulation of 
c-Myc by tylophorine compounds might play a significant 
role in the anti-cancer activity of these compounds.
The therapeutic targeting of RNP complexes 
represents an under-explored but emerging strategy for 
drug discovery[42]. RNPs are ribonucleoproteins in 
which RNA and protein molecules, such as the ribosome, 
the enzyme telomerase, hnRNP, small nuclear RNPs 
(snRNPs), and viral RNP complexes, interact. RNP 
complexes exhibit multiple roles, dynamic conformations, 
and chemical instability. Therefore, targeting RNPs for the 
discovery or development of therapeutic agents remains 
a challenge. However, several antiviral agents have been 
reported to target viral RNP complexes with high potency 
and exhibit significant potential for development into 
therapeutic drugs [43-45]. To the best of our knowledge, 
no anti-cancer agent targeting an RNP complex has been 
reported. We are the first to report that targeting an RNP 
complex (i.e., targeting the caprin-1 and c-Myc mRNA-
containing RNP complex by tylophorine compounds) in 
carcinoma cells can efficiently elicit anti-cancer activity. 
Significantly, pull-down experiments using 
biotinylated tylophorine revealed the association of 
caprin-1, G3BP1, c-Myc mRNA, and cyclins D1/D2 
mRNA in untreated carcinoma cell lysates (Fig. 1D and 
2B) in which the mRNAs for c-Myc and cyclin D1 and D2 
were not upregulated, as was observed in the tylophorine-
treated carcinoma cells (Fig. 2D-a). However, we did 
not observe the polysomal colocalization of G3BP1, 
c-Myc mRNA, and cyclins D1/D2 mRNA with caprin-1 
in the DMSO-treated carcinoma cells by sedimentation 
fractionation (Fig. 2D-b). Thus, we conclude that 
the binding of tylophorine to caprin-1 enhanced the 
recruitment of G3BP1, c-Myc mRNA, and cyclins D1/
D2 mRNA to the RNP complex. This hypothesis was also 
confirmed by the association of caprin-1 with G3BP1, 
c-Myc mRNA, and cyclins D1/D2 in polysomal fractions 
only in tylophorine- but not vehicle-treated carcinoma 
cells (Fig. 2D), whereas the c-Myc mRNA and cyclins 
D1/D2 mRNA levels were elevated in tylophorine-treated 
carcinoma cells (Fig. 2D-a and 3A).
The increased mRNA levels of c-Myc and cyclins 
D1 and D2 induced upon tylophorine treatment of 
the carcinoma cells might at least partially reflect an 
impairment of mRNA degradation due to tylophorine 
treatment, consistent with the dramatic decrease observed 
in the number of P-bodies, which suggested a blockade 
of cellular mRNA degradation processes. Moreover, 
cytoplasmic mRNAs cycle between polysomes, P-bodies 
and stress granules and translational repress can occur 
in these compartments through different mechanisms 
[46]. In addition to tylophorine treatment dramatically 
decreased the formation of P-bodies (Fig. 5C), stress 
granules were nearly not found either in DMSO or 
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Figure 6: The tylophorine compounds downregulate c-Myc protein levels and affect the expression of c-Myc target 
genes in carcinoma cells treated with tylophorine compounds in vitro or in vivo. A. Tylophorine and a tylophorine-derived-
dibenzoquinoline 33b (DBQ 33b) inhibited the protein expression of c-Myc in 13 carcinoma and 2 fibroblast cell lines. The results shown 
are representative of 3 independent experiments. B-D. The effects of tylophorine on the expression of c-Myc target genes. The results 
were obtained from an analysis of gene expression profiling with a cDNA-array (B) and verified by RT-qPCR (C). The genes regulated 
by the tylophorine compounds through c-Myc are listed by function and their upregulation or downregulation by c-Myc as determined 
in previous studies as indicated (D). Cells were treated with vehicle (0.1% DMSO), tylophorine (2 µM), or DBQ 33b (0.5 µM) for 24 h 
prior to lysis for western analysis with the indicated antibodies (A) or prior to mRNA extraction for gene expression profiling using the 
Illumina-HumanHT-12-v4 Expression-BeadChip (B) and RT-qPCR analysis (C). E & F. The protein (E) and mRNA (F) expression levels 
of c-Myc were downregulated in vivo in A549 xenograft tumors in mice by treatment with DBQ 33b[22]. (E) The protein expression of 
c-Myc detected by immunoblot analysis (upper panel) was quantitated and shown individually (lower panel). (F) The mRNA expression 
of c-Myc was analyzed by RT-qPCR; the products were shown in the upper panel, and the individual data were plotted in the lower panel. 
The relative expression levels of mRNA or protein were normalized with their respective internal loading control GAPDH. The sequences 
of the gene primer pairs used were listed in Supplemental Table 3. *, p<0.05; **, p<0.005; ***, p<0.0005; ****, p<0.0001.
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tylophorine treated carcinoma cells (Supplemental Figure 
1). Using TAMRA to label the newly synthesized protein 
by tylophorine treatment, we clearly demonstrated that 
tylophorine repressed the protein expression of c-Myc and 
cyclins D1/D2 (Fig. 3C). These results further firm that 
tylophorine sequestered the RNP containing caprin-1 and 
c-Myc mRNA in the polysomal fractions (Fig. 2D) and 
blocked the corresponding mRNAs’ translation. However, 
the detailed underlying mechanisms must be carefully 
addressed and further investigated. Our results suggest 
that caprin-1 is highly associated with the transport of 
c-Myc, cyclin D1, and cyclin D2 mRNAs for translation. 
Thus, the abrogation of this specific biological function of 
caprin-1 results in the induction of cell cycle arrest at the 
G1 phase[47].
The expression of c-Myc is elevated in numerous 
tumor types as the result of multiple mechanisms. c-Myc 
accumulates at the promoter regions of active genes in 
carcinoma cells, leading to their abnormal transcriptional 
amplification and oncogenicity [48]. Therefore, the 
upregulation of c-Myc is generally associated with tumor 
aggressiveness and poor clinical outcome. Thus, it is 
conceivable that the inhibition of c-Myc significantly 
contributes to the broad-spectrum anti-cancer activity of 
tylophorine compounds against drug-resistant carcinoma 
cells. Moreover, the induction of cell cycle arrest at G1[47] 
by knockdown of caprin-1 suggests that, in addition to the 
caprin-1 and c-Myc mRNA-associated RNP complex, 
Figure 7: A summary scheme for tylophorine-targeted anti-cancer pathways. The solid lines indicate the direct targeting of 
tylophorine compounds to caprin-1, c-Myc, and the related pathways. The dashed lines indicate the previously published c-Jun-mediated 
anti-cancer mechanism of tylophorine[25] including the results shown in Supplemental Figure 2 for decreased PTEN. The elevation 
of c-Jun by tylophorine compounds is not affected by ectopically overexpressed c-Myc as shown in Supplemental Figure 3 indicating 
that the tylophorine compounds target the caprin-1 and c-Myc mRNA-containing RNP complexes in parallel with their effects on c-Jun 
accumulation to elicit anti-cancer activity.
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caprin-1 itself may have favorable potential as a novel 
anti-cancer drug target. 
Ultimately, the blockade of c-Myc mRNA 
transport by the tylophorine-mediated sequester of the 
caprin-1, G3BP1, c-Myc mRNA, and cyclin D2 mRNA-
containing RNP complex may contribute significantly 
to the anti-cancer effects elicited by tylophorine in 
conjunction with the accumulation of c-Jun[25] (Fig. 
7). Tylophorine enhances the c-Jun downregulation of 
the cyclin A2 promoter activity and results in carcinoma 
cells dominantly arrested at G1 phase for anti-cancer 
activity[25]. The ectopically overexpressed c-Myc did not 
affect the accumulation of c-Jun induced by tylophorine 
treatment but did increase the expression of cyclin A2 via 
hyperphosphorylated pRb (Supplemental Figure 2 and 
Fig. 4B). Thus, we conclude that the elevation of c-Jun 
levels by tylophorine [23, 25] functions in concert with 
the targeting of the caprin-1 and c-Myc mRNA-containing 
RNP complex to produce the anti-cancer activity of 
tylophorine compounds (Fig. 7). 
MATERIALS AND METHODS 
Tylophorine compounds and biotinylated 
tylophorine (BT)
Tylophorine and DBQ 33b were prepared as 
described with a purity greater than 95% as determined 
by reverse pahse-HPLC[23]. The scheme for synthesis of 
biotinylated tylophorine, with purity of 95.87% analyzed 
by reverse pahse-HPLC, was shown in Figure 1A (see 
NMR data below and Supplemental Figure 4). 
Compound 1 was prepared as previously described 
[49] and reacted overnight with a mixture of NaH and 
tert-butyl (2-bromoethyl) carbamate in DMF to produce 
compound 2. We reduced compound 2 with LiAlH4 and 
AlCl3 (at a 3:1 ratio) in THF at room temperature for 4 h 
to produce compound 3. The N-Boc-protected amine was 
deprotected with H2SO4 in CH2Cl2 at room temperature 
for 22 h to produce compound 4. Finally, Biotin-X-SSE 
(Invitrogen) was coupled to compound 4 using Et3N in 
DMF at room temperature for 22 h to produce compound 
5, the biotinylated tylophorine, a tylophorine-based 
dibenzoquinoline derivative (Fig. 1A). Compound 5: 
Yellow crystal; 1H-NMR (300 MHz, CD3OD): 1.30-1.70 
(12H, m), 2.13 (2H, t, J=7.2 Hz), 2.24 (2H, m), 2.65 (1H, 
d, J=12.9 Hz), 2.85 (2H, dd, J=12.9 Hz, J=4.8 Hz), 2.99 
(2H, d, J=5.6 Hz), 3.11 (4H, t, J=7.2 Hz), 3.41 (2H,br d, 
J=16.8 Hz), 3.69 (2H, t, J=5.6 Hz), 4.02 (3H, s), 4.04 (3H, 
s), 4.08 (6H, s), 4.22 (1H, dd, J=8.0 Hz, J=4.5 Hz), 4.41 
(1H, dd, J=8.0 Hz, J=4.5 Hz), 4.50 (2H, s), 7.20 (1H, s), 
7.34 (1H, s), 7.93 (1H, s), 7.94 (1H, s). 13C-NMR (500 
MHz, CDCl3): 22.3, 24.5, 25.3, 26.1, 27.6, 27.8, 28.3, 
29.6, 34.0, 35.3, 36.0, 38.5, 40.6, 48.6, 51.1, 53.9, 55.6, 
56.0, 56.2, 59.7, 61.9, 102.7, 103.2, 103.4, 103.6, 117.7, 
122.7, 123.8, 124.0, 124.3, 149.2, 149.3, 149.6, 163.7, 
173.6, 175.4. ESI-MS m/z 758 (M + Na)+; HRMS calcd 
for C39H53O7N5NaS, 758.35579 (M
+); found, 758.35592.
Cell lines and culture
Two human fibroblast cell lines (Detroit 551 
[ATCC CCL-110]; WI-38 [ATCC CCL-75]), the human 
embryonic kidney cell line (HEK-293[ATCC CRL-
1573]), and 14 human carcinoma cell lines (breast, 
MCF7 [ATCC HTB-22], MCF7/ADR [ATCC], MDA-
MB-231 [BCRC 60425]; cervix, HeLa [BCRC 60005]; 
colon, DLD-1 [ATCC CCL-221], SW480 [ATCC CCL-
228]; gastric, NUGC-3 [the Japanese Cancer Research 
Resources Bank]; leukemia, U-937 [ATCC CRL-1593.2]; 
liver, HepG2 [ATCC HB-8065]; lung, A549 [ATCC CCL-
185](obtained from American Type Culture Collection 
and cultured for passages in fewer than 6 months from 
initial purchase); nasopharyngeal, HONE-1 [a gift from 
Dr. Ching-Hwa Tsai at National Taiwan University, 
Taiwan, ROC] (short tandem repeat (STR) profile was 
performed by Bioresource Collection and Research center 
(BCRC), Taiwan; The DNA profile was unique and no 
match was found in any known STR database, see data 
in Supplemental Table 4) ; pancreatic, AsPC-1[BCRC 
60494]; and prostate, DU 145 [ATCC HTB-81], PC-3 
[BCRC60122]) were used in this study. HEK-293, HeLa, 
HONE-1, MCF7, MCF7/ADR, HepG2, PC-3, NUGC-3, 
AsPC-1, Detroit 551, and WI-38 cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Hyclone 
Laboratory Inc.) supplemented with 10% fetal bovine 
serum (FBS, Hyclone Laboratory Inc.). DU 145 and 
U-937 cells were maintained in DMEM-FBS medium 
supplemented with 1 mM sodium pyruvate (GIBCO-
Life Technologies). DLD-1, A549, and MDA-MB-231 
cells were cultured in RPMI 1640 medium (GIBCO-Life 
Technologies) supplemented with 10% FBS, and SW480 
cells were maintained in RPMI 1640-FBS medium 
supplemented with 1 mM sodium pyruvate.
Cell Growth Inhibitory Assays
HONE-1, caprin-1 silencing HONE-1 cells (3000 
cells/well), MCF-7 (6500 cells/well ) and NUGC-3 (4500 
cells/well) were seeded into 96-well plates and subjected 
to measurement of growth inhibition by tylophorine, 
biotinlylated tylophorine, or DBQ 33b and the IC50 values 
were determined as previously described[18].
Pull-down assay and in-gel digestion
HONE-1 cell lysates were incubated with 
biotinylated tylophorine at 4°C for 4 h. The biotinylated 
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tylophorine-associated complexes were then pulled 
down using streptavidin Dynabeads M280 (Invitrogen) 
at 4°C for 1.5 h. The biotinylated tylophorine-bound 
proteins were eluted with Laemmli buffer and analyzed 
by electrophoresis on a 4%–20% gradient SDS-PAGE 
gel (W/H: 16 cm X 15 cm) and visualized by silver 
staining (Amersham Biosciences). The protein bands of 
interest were excised, subjected to in-gel digestion (see 
Supplemental Materials and Methods), and analyzed by 
LC/MS/MS using a Thermo Scientific LTQ XL mass 
spectrometer (Thermo Scientific). In addition, western 
blot was used to identify the protein components from 
the pull-down. The biotinylated tylophorine-bound RNAs 
were eluted with TRizol Reagent (Invitrogen) and RT-PCR 
was further used for analyzing the associated components.
Reverse transcription (RT) and quantitative 
polymerase chain reaction (qPCR) 
The previously described procedure was used[21]. 
The mRNA expression levels in Figures 2B, 2D, and 3A 
were determined by semi-RT-qPCR, analyzed using the 
Gel-Pro Analyzer program, and normalized using the 
housekeeping gene GAPDH when necessary. In Figure 6, 
the changes in mRNA expression levels were determined 
using the ∆∆CT method with GAPDH housekeeping 
genes. The primer pairs used in the PCR reactions are 
listed in Supplemental Table 3.
Western analyses and co-immunoprecipitation
We performed western blotting as previously 
described[18, 20] with antibody listed in Supplemental 
Table 5. See Supplemental Materials and Methods for 
co-immunoprecipitation using anti-caprin-1 antibody 
(ProteinTech Group).
Purification of recombinant human caprin-1 
expressed in HEK-293 cells
CAPRIN1-pCMV6-entry was obtained from 
Origene, and transfected in HEK-293 cells. Expressed 
caprin-1 was purified using anti-FLAG M2 affinity gel 
(Sigma-Aldrich). After washes with TBS buffer, the 
human caprin-1 protein was eluted with 3X Flag peptide 
(N-Met-Asp-Tyr-Lys-Asp-His-Asp-Gly-Asp-Tyr-Lys-
Asp-His-Asp-Ile-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-C, 
Sigma-Aldrich). 
Polysome profile analysis
HONE-1 cells were treated with 50 µg/ml 
cycloheximide at 37°C for 30 min before harvest. Total 
cell lysates were clarified by centrifugation at 4°C for 10 
min at 13,000 rpm. The supernatants were loaded on the 
top of a 10-50% sucrose gradient and ultracentrifuged in 
a SW41Ti Beckman rotor at 4°C for 4 h at 36,000 rpm. 
The fractions were collected from the bottom of the tubes, 
and the absorbance was measured at a wavelength of 254 
nm using an AKTA purifier (GE Healthcare, Amersham 
Biosciences). RNA and protein were extracted using 
TRIzol reagent (Invitrogen). Protein expression and 
mRNA expression were further analyzed by western 
immunoblot analysis and semi-RT-qPCR, respectively.
TAMRA Labeling and Detection of De Novo 
Synthesized Proteins of Interest
HONE-1 cells were washed with PBS and cultured 
with methionine-free DMEM (GIBCO-Life Technologies) 
at 37°C for 1 h prior to the addition of 2 μM tylophorine 
and 25 μM Click-iT® HPG (L-homopropargylglycine, 
Invitrogen) and incubation at 37°C for 24 h. The cells 
were then harvested and subjected to the Click Reaction 
with 20 μM TAMRA (Tetramethylrhodamine, Invitrogen) 
for labeling the de novo synthesized proteins in Click-iT® 
Protein Reaction Buffer according to the manufacturers’ 
protocol (Invitrogen). The resultant cell lysates were 
immunoprecipitated with anti-caprin-1 (ProteinTech 
Group), anti-c-Myc (Cell Signaling Technology), anti-
cyclin D1, anti-cyclin D2 (Santa Cruz Biotechnology), 
anti-TAMRA (Thermo Scientific) or GAR (Perkin-Elmer) 
respectively overnight at 4°C with constant agitation prior 
to incubation with protein G agarose (Millipore) at 4°C for 
another 2 h. After washes, the specific immunoprecipitated 
protein was eluted and analyzed by western immunoblot 
analysis with the antibody indicated. 
CAPRIN1 Gene Silencing
HONE-1 cells were transfected with CAPRIN1 
shRNA plasmid (TL312677, origene), or scrambled 
pGFP-C-shLenti shRNA (TR30021, origene) using 
FuGene 6TM (Roche). At 72 h post transfection, the cells 
were cultured in the presence of 1.5 mg/mL puromycin for 
selection. In addition, pseudotyped lentivirus containing 
CAPRIN1 shRNA (clone ID: TRCN0000115975 and 
TRCN0000115976) or negative control shRNA (shLacZ, 
clone ID: TRCN72224)(Academia Sinica, Taiwan) were 
transducted into HONE-1 cells with MOI of 3 in culture 
medium containing 8 μg/ml polybrene (Millipore). At 24 
h post transduction, the cells were cultured in the presence 
of 1.5 mg/mL puromycin for selection. 
Transfection
FuGene 6TM (Roche) was used for transient 
transfection of the constructs into HONE-1 cells according 
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to the manufacturers’ protocols. At 24 h after transfection, 
the HONE-1 cells were treated with either the vehicle 
control (0.1% DMSO) or 0.2 to 2 µM tylophorine for an 
additional 24 h. The cells were then harvested in lysis 
buffer as described above prior to immunoblot analyses. 
Plasmid constructs
The coding regions of human cyclin D1, 
cyclin D2, and c-Myc were amplified from 
HONE-1 cDNA using the following primer pairs: 
5’-CGGAATTCGGATGGAACACCAGCTCCTGTG-3’ 
& 5’-CCGCTCGAGTCAGATGTCCACGTCCCG-3’ 
for cyclin D1; 5’-AATGCAGCGATCGCCAT 
GGAGCTGCTGTGCCACGAGG-3’& 
5’-GTGACGACGCGTCAGGTCGATATCCCGCACGTC 
TGTA-3’ for cyclin D2; and 
5’-AATGCAGCGATCGCCCTGGATTTTTTTCGGGTA 
GTGGAAAACCAGCAGCCTCC-3’& 5’-GTGACGAC 
GCGTCGCACAAGAGTTCCGTAGCT GTTCAAGT-3’ 
for c-Myc. The coding regions were next subcloned into 
the EcoRI/XhoI site of pCMV-Myc and the AsiSI/MluI 
site of pCMV6-Entry to generate the CCND1-pCMV-
Myc, CCND2-pCMV6-Entry, and MYC-pCMV6-Entry 
expression vectors. The human CCNA2-pCMV-myc 
expression vector [20] was amplified from the MGC 
132447 clone (Open Biosystems) with primer pairs of 
5’-CGAATTCCGATGTTGGGCAACTCTGCG-3’ and 
5’-GCCTCGAGTTACAGATTTAGTGTCTCTGGTG 
G-3’, then subcloned into EcoRI/XhoI sites of pCMV-myc 
(Clontech). 
Immunoﬂuorescent assay (IFA) and confocal laser 
scanning microscopy. 
IFA were performed as described previously[21]. 
We used anti-DCP1a, anti-eIF4E, anti-G3BP1 (Santa Cruz 
Biotechnology) and anti-PABP (Abcam) antibodies to 
detect P-bodies and stress granules. Fluorescence imaging 
was performed using a Leica TSC SP5 laser-scanning 
confocal microscope.
Protein extraction from xenografted murine 
tumors
The xenografted murine tumor tissues [23] were 
flash-frozen in liquid nitrogen, washed with ice-cold 
PBS, and homogenized using a TissueLyser II (Qiagen) 
according to the manufacturer’s protocols. Total protein 
was extracted in lysis buffer as detailed above and further 
analyzed by western blotting. Total RNA was extracted 
using TRIzol Reagent (Invitrogen), reverse transcribed 
using Superscript III (Invitrogen), and analyzed by real-
time RT-qPCR as described above.
Gene expression profiling using cDNA arrays
HONE-1 cells were treated with the vehicle control 
(0.1% DMSO), 0.5 µM DBQ 33b, or 2 µM tylophorine. 
After treatment with the compounds for 24 h, total RNA 
was extracted using TRIzol reagent (Invitrogen), and 
expression profiling of the coding genes performed using 
the Illumina Human HT-12 v4 Expression BeadChip. 
Furthermore, the gene expression data from the Illumina 
arrays were validated by real-time RT-qPCR. 
CONFLICT OF INTEREST 
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
This work was funded by the National Science 
Council of Taiwan (NSC 102-2628-B-400-002-MY3), 
the National Health Research Institutes, Taiwan, R.O.C., 
and the Ministry of Economic Affairs, R.O.C. “102-EC-
17-A-02-04-1099” & “103-EC-17-A-22-1099”. Y-Q Qiu 
is currently a PhD student in the Graduate Program of 
Biotechnology in Medicine, which is sponsored by the 
National Health Research Institutes and National Tsing 
Hua University. We would like to acknowledge the NHRI 
Optical Biology Core Facility for their assistance with 
confocal microscopy.
REFERENCES
1. Mateyak MK, Obaya AJ and Sedivy JM. c-Myc regulates 
cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle 
progression at multiple independent points. Molecular and 
cellular biology. 1999; 19(7):4672-4683.
2. Dang CV, Le A and Gao P. MYC-induced cancer cell 
energy metabolism and therapeutic opportunities. Clinical 
cancer research. 2009; 15(21):6479-6483.
3. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi 
T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT 
and Dang CV. c-Myc suppression of miR-23a/b enhances 
mitochondrial glutaminase expression and glutamine 
metabolism. Nature. 2009; 458(7239):762-765.
4. Jones RM, Branda J, Johnston KA, Polymenis M, Gadd 
M, Rustgi A, Callanan L and Schmidt EV. An essential E 
box in the promoter of the gene encoding the mRNA cap-
binding protein (eukaryotic initiation factor 4E) is a target 
for activation by c-myc. Molecular and cellular biology. 
1996; 16(9):4754-4764.
5. Labisso WL, Wirth M, Stojanovic N, Stauber RH, Schnieke 
A, Schmid RM, Kramer OH, Saur D and Schneider G. 
MYC directs transcription of MCL1 and eIF4E genes to 
control sensitivity of gastric cancer cells toward HDAC 
inhibitors. Cell cycle. 2012; 11(8):1593-1602.
Oncotarget2162www.impactjournals.com/oncotarget
6. Kim HH, Kuwano Y, Srikantan S, Lee EK, Martindale JL 
and Gorospe M. HuR recruits let-7/RISC to repress c-Myc 
expression. Genes & development. 2009; 23(15):1743-
1748.
7. Adams PD. Regulation of the retinoblastoma tumor 
suppressor protein by cyclin/cdks. Biochimica et biophysica 
acta. 2001; 1471(3):M123-133.
8. Paternot S, Arsenijevic T, Coulonval K, Bockstaele L, 
Dumont JE and Roger PP. Distinct specificities of pRb 
phosphorylation by CDK4 activated by cyclin D1 or cyclin 
D3: differential involvement in the distinct mitogenic 
modes of thyroid epithelial cells. Cell cycle. 2006; 5(1):61-
70.
9. Tashiro E, Maruki H, Minato Y, Doki Y, Weinstein IB 
and Imoto M. Overexpression of cyclin D1 contributes to 
malignancy by up-regulation of fibroblast growth factor 
receptor 1 via the pRB/E2F pathway. Cancer research. 
2003; 63(2):424-431.
10. Sweeney KJ, Sarcevic B, Sutherland RL and Musgrove EA. 
Cyclin D2 activates Cdk2 in preference to Cdk4 in human 
breast epithelial cells. Oncogene. 1997; 14(11):1329-1340.
11. Arvanitakis L, Yaseen N and Sharma S. Latent 
membrane protein-1 induces cyclin D2 expression, pRb 
hyperphosphorylation, and loss of TGF-beta 1-mediated 
growth inhibition in EBV-positive B cells. The Journal of 
Immunology. 1995; 155(3):1047-1056.
12. Seville LL, Shah N, Westwell AD and Chan WC. 
Modulation of pRB/E2F functions in the regulation of cell 
cycle and in cancer. Current cancer drug targets. 2005; 
5(3):159-170.
13. Solomon S, Xu Y, Wang B, David MD, Schubert P, 
Kennedy D and Schrader JW. Distinct structural features 
of caprin-1 mediate its interaction with G3BP-1 and its 
induction of phosphorylation of eukaryotic translation 
initiation factor 2alpha, entry to cytoplasmic stress 
granules, and selective interaction with a subset of mRNAs. 
Molecular and cellular biology. 2007; 27(6):2324-2342.
14. Harvey AL. Natural products in drug discovery. Drug 
discovery today. 2008; 13(19-20):894-901.
15. Gu J, Gui Y, Chen L, Yuan G, Lu HZ and Xu X. Use of 
natural products as chemical library for drug discovery and 
network pharmacology. PloS one. 2013; 8(4):e62839.
16. Lee YZ, Yang CW, Chang HY, Hsu HY, Chen IS, Chang 
HS, Lee CH, Lee JC, Kumar CR, Qui YQ, Chao YS and 
Lee SJ. Discovery of selective inhibitors of Glutaminase-2, 
which inhibit mTORC1, activate autophagy and inhibit 
proliferation in cancer cells. Oncotarget .2014;5(15):6087-
6101. 
17. Suffness M and Douros J. (1980). Anticancer agents based 
on natural product models: Academic Press).
18. Yang CW, Chen WL, Wu PL, Tseng HY and Lee SJ. 
Anti-inflammatory mechanisms of phenanthroindolizidine 
alkaloids. Molecular pharmacology. 2006; 69(3):749-758.
19. Yang CW, Chuang TH, Wu PL, Huang WH and Lee SJ. 
Anti-inflammatory effects of 7-methoxycryptopleurine and 
structure-activity relations of phenanthroindolizidines and 
phenanthroquinolizidines. Biochemical and biophysical 
research communications. 2007; 354(4):942-948.
20. Wu CM, Yang CW, Lee YZ, Chuang TH, Wu PL, Chao YS 
and Lee SJ. Tylophorine arrests carcinoma cells at G1 phase 
by downregulating cyclin A2 expression. Biochemical and 
biophysical research communications. 2009; 386(1):140-
145.
21. Yang CW, Lee YZ, Kang IJ, Barnard DL, Jan JT, Lin D, 
Huang CW, Yeh TK, Chao YS and Lee SJ. Identification 
of phenanthroindolizines and phenanthroquinolizidines 
as novel potent anti-coronaviral agents for porcine 
enteropathogenic coronavirus transmissible gastroenteritis 
virus and human severe acute respiratory syndrome 
coronavirus. Antiviral research. 2010; 88(2):160-168.
22. Lee YZ, Huang CW, Yang CW, Hsu HY, Kang IJ, 
Chao YS, Chen IS, Chang HY and Lee SJ. Isolation and 
biological activities of phenanthroindolizidine and septicine 
alkaloids from the Formosan Tylophora ovata. Planta 
medica. 2011; 77(17):1932-1938.
23. Lee YZ, Yang CW, Hsu HY, Qiu YQ, Yeh TK, Chang HY, 
Chao YS and Lee SJ. Synthesis and biological evaluation 
of tylophorine-derived dibenzoquinolines as orally active 
agents: exploration of the role of tylophorine e ring on 
biological activity. Journal of medicinal chemistry. 2012; 
55(23):10363-10377.
24. Chemler SR. Phenanthroindolizidines and 
Phenanthroquinolizidines: Promising Alkaloids for Anti-
Cancer Therapy. Current bioactive compounds. 2009; 
5(1):2-19.
25. Yang CW, Lee YZ, Hsu HY, Wu CM, Chang HY, Chao 
YS and Lee SJ. c-Jun-mediated anticancer mechanisms of 
tylophorine. Carcinogenesis. 2013; 34:1304-1314.
26. Gao W, Lam W, Zhong S, Kaczmarek C, Baker DC and 
Cheng YC. Novel mode of action of tylophorine analogs as 
antitumor compounds. Cancer research. 2004; 64(2):678-
688.
27. Meng X, Zhang Y, Jia Z, Huo X, He X, Tian G, Wu M, 
Wang Z, Zhou X, Xiong S, Gao X, Wu Z, Han J, et al. 
A novel tylophorine analog W-8 up-regulates forkhead 
boxP3 expression and ameliorates murine colitis. Journal 
of leukocyte biology. 2013; 93(1):83-93.
28. Yang X, Shi Q, Lai CY, Chen CY, Ohkoshi E, Yang SC, 
Wang CY, Bastow KF, Wu TS, Pan SL, Teng CM, Yang 
PC and Lee KH. Antitumor agents 295. E-ring hydroxylated 
antofine and cryptopleurine analogues as antiproliferative 
agents: design, synthesis, and mechanistic studies. Journal 
of medicinal chemistry. 2012; 55(15):6751-6761.
29. Huang MT and Grollman AP. Mode of action of 
tylocrebrine: effects on protein and nucleic acid synthesis. 
Molecular pharmacology. 1972; 8(5):538-550.
30. Zhou Q, Stetler-Stevenson M and Steeg PS. Inhibition of 
cyclin D expression in human breast carcinoma cells by 
Oncotarget2163www.impactjournals.com/oncotarget
retinoids in vitro. Oncogene. 1997; 15(1):107-115.
31. Parker BS, Cutts SM, Nudelman A, Rephaeli A, Phillips 
DR and Sukumar S. Mitoxantrone mediates demethylation 
and reexpression of cyclin d2, estrogen receptor and 
14.3.3sigma in breast cancer cells. Cancer biology & 
therapy. 2003; 2(3):259-263.
32. Evron E, Umbricht CB, Korz D, Raman V, Loeb 
DM, Niranjan B, Buluwela L, Weitzman SA, Marks 
J and Sukumar S. Loss of cyclin D2 expression in the 
majority of breast cancers is associated with promoter 
hypermethylation. Cancer research. 2001; 61(6):2782-2787.
33. Bowe DB, Kenney NJ, Adereth Y and Maroulakou IG. 
Suppression of Neu-induced mammary tumor growth in 
cyclin D1 deficient mice is compensated for by cyclin E. 
Oncogene. 2002; 21(2):291-298.
34. Lam EW, Glassford J, Banerji L, Thomas NS, Sicinski P 
and Klaus GG. Cyclin D3 compensates for loss of cyclin D2 
in mouse B-lymphocytes activated via the antigen receptor 
and CD40. The Journal of biological chemistry. 2000; 
275(5):3479-3484.
35. Blanchard JM. Cyclin A2 transcriptional regulation: 
modulation of cell cycle control at the G1/S transition 
by peripheral cues. Biochemical pharmacology. 2000; 
60(8):1179-1184.
36. Daksis JI, Lu RY, Facchini LM, Marhin WW and Penn 
LJ. Myc induces cyclin D1 expression in the absence of de 
novo protein synthesis and links mitogen-stimulated signal 
transduction to the cell cycle. Oncogene. 1994; 9(12):3635-
3645.
37. Perez-Roger I, Kim SH, Griffiths B, Sewing A and Land 
H. Cyclins D1 and D2 mediate myc-induced proliferation 
via sequestration of p27(Kip1) and p21(Cip1). The EMBO 
journal. 1999; 18(19):5310-5320.
38. Seo HR, Kim J, Bae S, Soh JW and Lee YS. Cdk5-
mediated phosphorylation of c-Myc on Ser-62 is essential 
in transcriptional activation of cyclin B1 by cyclin G1. 
The Journal of biological chemistry. 2008; 283(23):15601-
15610.
39. Kedersha N, Tisdale S, Hickman T and Anderson P. Real-
time and quantitative imaging of mammalian stress granules 
and processing bodies. Methods in enzymology. 2008; 
448:521-552.
40. Lee HC, Cho H and Kim YK. Ectopic expression of eIF4E-
transporter triggers the movement of eIF4E into P-bodies, 
inhibiting steady-state translation but not the pioneer 
round of translation. Biochemical and biophysical research 
communications. 2008; 369(4):1160-1165.
41. Kedersha N, Stoecklin G, Ayodele M, Yacono P, Lykke-
Andersen J, Fritzler MJ, Scheuner D, Kaufman RJ, Golan 
DE and Anderson P. Stress granules and processing bodies 
are dynamically linked sites of mRNP remodeling. The 
Journal of cell biology. 2005; 169(6):871-884.
42. DeJong ES, Luy B and Marino JP. RNA and RNA-protein 
complexes as targets for therapeutic intervention. Current 
topics in medicinal chemistry. 2002; 2(3):289-302.
43. Zhang W, Du J, Yu K, Wang T, Yong X and Yu XF. 
Association of potent human antiviral cytidine deaminases 
with 7SL RNA and viral RNP in HIV-1 virions. Journal of 
virology. 2010; 84(24):12903-12913.
44. Amorim MJ, Kao RY and Digard P. Nucleozin targets 
cytoplasmic trafficking of viral ribonucleoprotein-Rab11 
complexes in influenza A virus infection. Journal of 
virology. 2013; 87(8):4694-4703.
45. He J, Qi WB, Wang L, Tian J, Jiao PR, Liu GQ, Ye WC 
and Liao M. Amaryllidaceae alkaloids inhibit nuclear-to-
cytoplasmic export of ribonucleoprotein (RNP) complex of 
highly pathogenic avian influenza virus H5N1. Influenza 
and other respiratory viruses. 2013; 7(6):922-931.
46. Balagopal V and Parker R. Polysomes, P bodies and stress 
granules: states and fates of eukaryotic mRNAs. Current 
opinion in cell biology. 2009; 21(3):403-408.
47. Wang B, David MD and Schrader JW. Absence of caprin-1 
results in defects in cellular proliferation. The Journal of 
Immunology. 2005; 175(7):4274-4282.
48. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner 
JE, Lee TI and Young RA. Transcriptional amplification in 
tumor cells with elevated c-Myc. Cell. 2012; 151(1):56-67.
49. Chuang TH, Lee SJ, Yang CW and Wu PL. Expedient 
synthesis and structure-activity relationships of 
phenanthroindolizidine and phenanthroquinolizidine 
alkaloids. Organic & biomolecular chemistry. 2006; 
4(5):860-867.
